G-quadruplex structures in the human genome as novel therapeutic targets

Molecules

Volumn 18, Issue 10, 2013, Pages 12368-12395

  Bidzinska, Joanna ^a   Cimino Reale, Graziella ^a   Zaffaroni, Nadia ^a   Folini, Marco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

G quadruplex; Oncogene; Small molecules; Telomeres

Indexed keywords

ANTINEOPLASTIC AGENT; GUANINE QUADRUPLEX;

ANIMAL; GENETICS; HUMAN; HUMAN GENOME; MOLECULARLY TARGETED THERAPY; NEOPLASM; NUCLEOTIDE SEQUENCE; REVIEW; TELOMERE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; G-QUADRUPLEXES; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TELOMERE;

EID: 84886626805     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules181012368     Document Type: Review

References (108)

1. Balasubramanian, S.; Hurley, L.H.; Neidle, S. Targeting G-quadruplexes in gene promoters: A novel anticancer strategy? Nat. Rev. Drug Discov. 2011, 10, 261-275.
2. Collie, G.W.; Parkinson, G.N. The application of DNA and RNA G-quadruplexes to therapeutic medicines. Chem. Soc. Rev. 2011, 40, 5867-5892.
3. Bugaut, A.; Balasubramanian, S. 5′-UTR RNA G-quadruplexes: Translation regulation and targeting. Nucleic Acids Res. 2012, 40, 4727-4741.
4. Neidle, S. The structures of quadruplex nucleic acids and their drug complexes. Curr. Opin. Struct. Biol. 2009, 19, 239-250.
5. Balasubramanian, S.; Neidle, S. G-quadruplex nucleic acids as therapeutic targets. Curr. Opin. Chem. Biol. 2009, 13, 345-353.
6. Bochman, M.L.; Paeschke, K.; Zakian, V.A. DNA secondary structures: Stability and function of G-quadruplex structures. Nat. Rev. Genet. 2012, 13, 770-780.
7. Du, Y.; Zhou, X. Targeting non-B-form DNA in living cells. Chem. Record 2013, 13, 371-384.
8. Vy Thi Le, T.; Han, S.; Chae, J.; Park, H.J. G-quadruplex binding ligands: From naturally occurring to rationally designed molecules. Curr. Pharm. Des. 2012, 18, 1948-1972.
9. Conomos, D.; Pickett, H.A.; Reddel, R.R. Alternative lengthening of telomeres: Remodeling the telomere architecture. Front. Oncol. 2013, doi:10.3389/fonc.2013.00027.
10. Mocellin, S.; Pooley, K.A.; Nitti, D. Telomerase and the search for the end of cancer. Trends Mol. Med. 2013, 19, 125-133.
11. Sprouse, A.A.; Steding, C.E.; Herbert, B.S. Pharmaceutical regulation of telomerase and its clinical potential. J. Cell. Mol. Med. 2012, 16, 1-7.
12. Cairney, C.J.; Hoare, S.F.; Daidone, M.G.; Zaffaroni, N.; Keith, W.N. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br. J. Cancer 2008, 98, 1467-1474.
13. Heaphy, C.M.; de Wilde, R.F.; Jiao, Y.; Klein, A.P.; Edil, B.H.; Shi, C.; Bettegowda, C.; Rodriguez, F.J.; Eberhart, C.G.; Hebbar, S.; et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333, 425.
14. Marian, C.O.; Cho, S.K.; McEllin, B.M.; Maher, E.A.; Hatanpaa, K.J.; Madden, C.J.; Mickey, B.E.; Wright, W.E.; Shay, J.W.; Bachoo, R.M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16, 154-163.
15. Hu, J.; Hwang, S.S.; Liesa, M.; Gan, B.; Sahin, E.; Jaskelioff, M.; Ding, Z.; Ying, H.; Boutin, A.T.; Zhang, H.; et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012, 148, 651-663.
16. Bryan, T.M.; Baumann, P. G-quadruplexes: From guanine gels to chemotherapeutics. Mol. Biotechnol. 2011, 49, 198-208.
17. Hänsel, R.; Löhr, F.; Trantirek, L.; Dötsch, V. High-Resolution insight into G-overhang architecture. J. Am. Chem. Soc. 2013, 135, 2816-2824.
18. Dai, J.; Carver, M.; Yang, D. Polymorphism of human telomeric quadruplex structures. Biochimie 2008, 90, 1172-1183.
19. Parkinson, G.N.; Cuenca, F.; Neidle, S. Topology conservation and loop flexibility in quadruplex-drug recognition: Crystal structures of inter- and intramolecular telomeric DNA quadruplex-drug complexes. J. Mol. Biol. 2008, 381, 1145-1156.
20. Bazzicalupi, C.; Ferraroni, M.; Bilia, A.R.; Scheggi, F.; Gratteri, P. The crystal structure of human telomeric DNA complexed with berberine: An interesting case of stacked ligand to G-tetrad ratio higher than 1:1. Nucleic Acids Res. 2013, 41, 632-638.
21. Sun, D.; Thompson, B.; Cathers, B.E.; Salazar, M.; Kerwin, S.M.; Trent, J.O.; Jenkins, T.C.; Neidle, S.; Hurley, L.H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40, 2113-2116.
22. Xu, Y. Chemistry in human telomere biology: Structure, function and targeting of telomere DNA/RNA. Chem. Soc. Rev. 2011, 40, 2719-2740.
23. Castillo-González, D.; Pérez-Machado, G.; Guédin, A.; Mergny, J.L.; Cabrera-Pérez, M.A. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA. Curr. Pharm. Des. 2013, 19, 2164-2173.
24. Alcaro, S.; Musetti, C.; Distinto, S.; Casatti, M.; Zagotto, G.; Artese, A.; Parrotta, L.; Moraca, F.; Costa, G.; Ortuso, F.; et al. Identification and characterization of new DNA G-quadruplex binders selected by a combination of ligand and structure-based virtual screening approaches. J. Med. Chem. 2013, 56, 843-855.
25. Yang, D.; Okamoto, K. Structural insights into G-quadruplexes: Towards new anticancer drugs. Future Med. Chem. 2010, 619-646.
26. De Cian, A.; Lacroix, L.; Douarre, C.; Temime-Smaali, N.; Trentesaux, C.; Riou, J.F.; Mergny, J.L. Targeting telomeres and telomerase. Biochimie 2008, 90, 131-155.
27. Folini, M.; Venturini, L.; Cimino-Reale, G.; Zaffaroni, N. Telomeres as targets for anticancer therapies. Expert Opin. Ther. Targets 2011, 15, 579-593.
28. Temime-Smaali, N.; Guittat, L.; Sidibe, A.; Shin-ya, A.; Trentesaux, C. The G-quadruplex ligand telomestatitn impairs binding of topoisomerase III alpha to G-quadruplex forming oligonucleotides and uncaps telomeres in ALT cells. PLoS One 2009, 4, e6919.
29. Salvati, E.; Leonetti, C.; Rizzo, A.; Scarsell, M.; Mottolese, M.; Galati, R.; Stevens, M.F.; D'Incalci, M.; Blasco, M.; Chiorino, G.; et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 2007, 117, 3236-3247.
30. Leonetti, C.; Scarsella, M.; Riggio, G.; Rizzo, A.; Salvati, E.; D'Incalci, M.; Staszewsky, L.; Frapolli, R.; Stevens, M.F.; Stoppacciaro, A.; et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin. Cancer Res. 2008, 14, 7284-7291.
31. Gunaratnam, M.; de la Fuente, M.; Hampel, S.M.; Todd, A.K.; Reszka, A.P.; Schätzlein, A.; Neidle, S. Targeting pancreatic cancer with a G-quadruplex ligand. Bioorg. Med. Chem. 2011, 19, 7151-7157.
32. Doria, F.; Nadai, M.; Folini, M.; di Antonio, M.; Germani, L.; Percivalle, C.; Sissi, C.; Zaffaroni, N.; Alcaro, S.; Artese, A.; et al. Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures. Org. Biomol. Chem. 2012, 10, 2798-27806.
33. Micco, M.; Collie, G.W.; Dale, A.G.; Ohnmacht, S.A.; Pazitna, I.; Gunaratham, M.; Reszka, A.P.; Neidle, S. Structure-based design and evaluation of naphthalene diimide G-quadruplex ligands as telomere targeting agents in pancreatic cancer cells. J. Med. Chem. 2013, 56, 2959-2974.
34. Huang, F.C.; Chang, C.C.; Lou, P.J.; Kuo, I.C.; Chien, C.W.; Chen, C.T.; Shieh, F.Y.; Chang, T.C.; Lin, J.J. G-quadruplex stabilizer 3,6-bis(1-methyl-4- vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol. Cancer Res. 2008, 6, 955-964.
35. Muller, S.; Sanders, D.A.; di Antonio, M.; Matsis, S.; Riou, J.F.; Balasubramanian, S. Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. Org. Biomol. Chem. 2012, 10, 6537-6546.
36. Huang, F.C.; Chang, C.C.; Wang, J.M.; Chang, T.C.; Lin, J.J. Induction of senescence in cancer cells by the G-quadruplex stabilizer, BMVC4, is independent of its telomerase inhibitory activity. Br. J. Pharmacol. 2012, 167, 393-406.
37. Riou, J.F.; Gomez, D.; Morjani, H.; Trentesaux, C. Quadruplex Ligand Recognition: Biological Aspects. In Quadruplex Nucleic Acids; Neidle, S., Balasubramanian, S., Eds.; The Royal Society of Chemistry: London, UK, 2006; Chapter 6, pp. 154-180.
38. Zaug, A.J.; Podell, E.R.; Cech, T.R. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 10864-10869.
39. Yang, Q.; Zheng, Y.L.; Harris, C.C. POT1 and TRF2 cooperate to maintain telomeric integrity. Mol. Cell. Biol. 2005, 25, 1070-1080.
40. Orlotti, N.I.; Cimino-Reale, G.; Borghini, E.; Pennati, M.; Sissi, C.; Perrone, F.; Palumbo, M.; Daidone, M.G.; Folini, M.; Zaffaroni, N. Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy 2012, 8, 1185-1196.
41. Azzalin, C.M.; Lingner, J. Telomeres: The silence is broken. Cell Cycle 2008, 7, 1161-1165.
42. Nergadze, S.G.; Farnung, B.O.; Wischnewski, H.; Khoriauli, L.; Vitelli, V.; Chawla, R.; Giulotto, E.; Azzalin, C.M. CpG-island promoters drive transcription of human telomeres. RNA 2009, 15, 2186-2194.
43. Redon, S.; Reichenbach, P.; Lingner, J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic Acids Res. 2010, 38, 5797-5806.
44. Deng, Z.; Norseen, J.; Wiedmer, A.; Riethman, H.; Lieberman, P.M. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol. Cell 2009, 35, 403-413.
45. Luke, B.; Lingner, J. TERRA: Telomeric repeat-containing RNA. EMBO J. 2009, 28, 2503-2510.
46. Ng, L.J.; Cropley, J.E.; Pickett, H.A.; Reddel, R.R.; Suter, C.M. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res. 2009, 37, 1152-1159.
47. Schoeftner, S.; Blasco, M.A. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat. Cell. Biol. 2008, 10, 228-236.
48. Sampl, S.; Pramhas, S.; Stern, C.; Preusser, M.; Marosi, C.; Holzmann, K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl. Oncol. 2012, 5, 56-65.
49. Deng, Z.; Wang, Z.; Xiang, C.; Molczan, A.; Baubet, V.; Conejo-Garcia, J.; Xu, X.; Lieberman, P.M.; Dahmane, N. Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. J. Cell Sci. 2012, 125, 4383-4394.
50. Zhang, Q.S.; Manche, L.; Xu, R.M.; Krainer, A.R. hnRNP A1 associates with telomere ends and stimulates telomerase activity. RNA 2006, 12, 1116-1128.
51. Xu, Y.; Kaminaga, K.; Komiyama, M. Human telomeric RNA in G-quadruplex structure. Nucleic Acids Symp. Ser. (Oxf.) 2008, 52, 175-176.
52. Xu, Y.; Kimura, T.; Komiyama, M. Human telomere RNA and DNA form an intermolecular G-quadruplex. Nucleic Acids Symp. Ser. (Oxf.) 2008, 52, 169-170.
53. Martadinata, H.; Phan, A.T. Structure of propeller-type parallel-stranded RNA G-quadruplexes, formed by human telomeric RNA sequences in K+ solution. J. Am. Chem. Soc. 2009, 131, 2570-2578.
54. Xu, Y.; Suzuki, Y.; Ito, K.; Komiyama, M. Telomeric repeat-containing RNA structure in living cells. Proc. Natl. Acad. Sci. USA 2010, 107, 14579-14584.
55. Collie, G.; Reszka, A.P.; Haider, S.M.; Gabelica, V.; Parkinson, G.N.; Neidle, S. Selectivity in small molecule binding to human telomeric RNA and DNA quadruplexes. Chem. Commun. 2009, 48, 7482-7484.
56. Collie, G.W.; Sparapani, S.; Parkinson, G.N.; Neidle, S. Structural basis of telomeric RNA quadruplex-acridine ligand recognition. J. Am. Chem. Soc. 2011, 133, 2721-2728.
57. Maizels, N. G4 motifs in human genes. Ann. N. Y. Acad. Sci. 2012, 1267, 53-60.
58. Delgado, M.D.; Albajar, M.; Gomez-Casares, M.T.; Batlle, A.; León, J. MYC oncogene in myeloid neoplasias. Clin. Transl. Oncol. 2013, 15, 87-94.
59. González, V.; Hurley, L.H. The c-MYC NHE III (1): Function and regulation. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 111-129.
60. Siddiqui-Jain, A.; Grand, C.L.; Bearss, D.J.; Hurley, L.H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. USA 2002, 99, 11593-11598.
61. Brooks, T.A.; Hurley, L.H. Targeting MYC expression through G-Quadruplexes. Genes Cancer 2010, 1, 641-649.
62. Ou, T.M.; Lu, Y.J.; Zhang, C.; Huang, Z.S.; Wang, X.D.; Tan, J.H.; Chen, Y.; Ma, D.L.; Wong, K.Y.; Tang, J.C.; et al. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J. Med. Chem. 2007, 50, 1465-1474.
63. Brown, R.V.; Danford, F.L.; Gokhale, V.; Hurley, L.H.; Brooks, T.A. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J. Biol. Chem. 2011, 286, 41018-41027.
64. Palumbo, L.; Ebbinghaus, S.W.; Hurley, L.H. Formation of a unique end-to-end stacked pair of G-quadruplex in the TERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J. Am. Chem. Soc. 2009, 131, 10878-10891.
65. Taka, T.; Huang, L.; Wongnoppavich, A.; Tam-Chang, S.W.; Lee, T.R.; Tuntiwechapikul, W. Telomere shortening and cell senescence induced by perylene derivatives in A549 human lung cancer cells. Bioorg. Med. Chem. 2013, 21, 883-890.
66. Ashman, L.K.; Griffith, R. Therapeutic targeting of c-KIT in cancer. Expert Opin. Investig. Drugs 2013, 22, 103-115.
67. Rankin, S.; Reszka, A.P.; Huppert, J.; Zloh, M.; Parkinson, G.N.; Todd, A.K.; Ladame, S.; Balasubramanian, S.; Neidle, S. Putative DNA quadruplex formation within the human c-kit oncogene. J. Am. Chem. Soc. 2005, 127, 10584-10589.
68. Fernando, H.; Reszka, A.P.; Huppert, J.; Ladame, S.; Rankin, S.; Venkitaraman, A.R.; Neidle, S.; Balasubramanian, S. A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry 2006, 45, 7854-7860.
69. Bejugam, M.; Sewitz, S.; Shirude, P.S.; Rodriguez, R.; Shahid, R.; Balasubramanian, S. Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: Small molecule regulation of c-kit oncogene expression. J. Am. Chem. Soc. 2007, 129, 12926-12927.
70. Dash, J.; Shirude, P.S.; Balasubramanian, S. G-quadruplex recognition by bis-indole carboxamides. Chem. Commun. (Camb.) 2008, 26, 3055-3057.
71. McLuckie, K.I.; Waller, Z.A.; Sanders, D.A.; Alves, D.; Rodriguez, R.; Dash, J.; McKenzie, G.J.; Venkitaraman, A.R.; Balasubramanian, S. G-quadruplex-binding benzo[a]phenoxazines down-regulate c-KIT expression in human gastric carcinoma cells. J. Am. Chem. Soc. 2011, 133, 2658-2663.
72. Gunaratnam, M.; Swank, S.; Haider, S.M.; Galesa, K.; Reszka, A.P.; Beltran, M.; Cuenca, F.; Fletcher, J.A.; Neidle, S. Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J. Med. Chem. 2009, 52, 3774-3783.
73. Waller, Z.A.; Sewitz, S.A.; Hsu, S.D.; Balasubramanian, S. A small molecule that disrupts G-quadruplex DNA structure and enhances gene expression. J. Am. Chem. Soc. 2009, 131, 12628-12633.
74. Ibáñez, C.F. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 2013, 5, a009134.
75. Guo, K.; Pourpak, A.; Beetz-Rogers, K.; Gokhale, V.; Sun, D.; Hurley, L.H. Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J. Am. Chem. Soc. 2007, 129, 10220-10228.
76. Tong, X.; Lan, W.; Zhang, X.; Wu, H.; Liu, M.; Cao, C. Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence. Nucleic Acids Res. 2011, 39, 6753-6763.
77. Ji, Z.; Flaherty, K.T.; Tsao, H. Targeting the RAS pathway in melanoma. Trends Mol. Med. 2012, 18, 27-35.
78. Cogoi, S.; Xodo, L.E. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res. 2006, 34, 2536-2549.
79. Cogoi, S.; Paramasivam, M.; Filichev, V.; Géci, I.; Pedersen, E.B.; Xodo, L.E. Identification of a new G-quadruplex motif in the KRAS promoter and design of pyrene-modified G4-decoys with antiproliferative activity in pancreatic cancer cells. J. Med. Chem. 2009, 52, 564-568.
80. Lavrado, J.; Borralho, P.M.; Ohnmacht, S.A.; Castro, R.E.; Rodrigues, C.M.; Moreira, R.; Santos, D.J.; Neidle, S.; Paulo, A. Synthesis, G-quadruplex stabilisation, docking studies, and effect on cancer cells of indolo[3,2-b]quinolines with one, two, or three basic side chains. Chem Med Chem 2013, doi:10.1002/cmdc.201300288.
81. Membrino, A.; Cogoi, S.; Pedersen, E.B.; Xodo, L.E. G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. PLoS One 2011, 6, e24421.
82. Tomek, M.; Akiyama, T.; Dass, C.R. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J. Pharm. Pharmacol. 2012, 64, 1695-1702.
83. Thomas, S.; Quinn, B.A.; Das, S.K.; Dash, R.; Emdad, L.; Dasgupta, S.; Wang, X.Y.; Dent, P.; Reed, J.C.; Pellecchia, M.; et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin. Ther. Targets 2013, 17, 61-75.
84. Dexheimer, T.S.; Sun, D.; Hurley, L.H. Deconvoluting the structural and drug-recognition complexity of the G-quadruplex-forming region upstream of the bcl-2 P1 promoter. J. Am. Chem. Soc. 2006, 128, 5404-5415.
85. Wang, X.D.; Ou, T.M.; Lu, Y.J.; Li, Z.; Xu, Z.; Xi, C.; Tan, J.H.; Huang, S.L.; An, L.K.; Li, D.; et al. Turning off transcription of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with quindoline derivatives. J. Med. Chem. 2010, 53, 4390-4398.
86. Greer, S.N.; Metcalf, J.L.; Wang, Y.; Ohh, M. The updated biology of hypoxia-inducible factor. EMBO J. 2012, 31, 2448-2460.
87. De Armond, R.; Wood, S.; Sun, D.; Hurley, L.H.; Ebbinghaus, S.W. Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1alpha promoter. Biochemistry 2005, 44, 16341-1650.
88. Lombardo, C.M.; Welsh, S.J.; Strauss, S.J.; Dale, A.G.; Todd, A.K.; Nanjunda, R.; Wilson, D.W.; Neidle, S. A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines. Bioorg. Med. Chem. Lett. 2012, 22, 5984-5988.
89. Brooks, T.A.; Kendrick, S.; Hurley, L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. FEBS J. 2010, 277, 3459-3469.
90. Rodriguez, R.; Miller, K.M.; Forment, J.V.; Bradshaw, C.R.; Nikan, M.; Britton, S.; Oelschlaegel, T.; Xhemalce, B.; Balasubramanian S.; Jackson S.P. Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat. Chem. Biol. 2012, 8, 301-310.
91. Aleshin, A.; Finn, R.S. SRC: A century of science brought to the clinic. Neoplasia 2010, 12, 599-607.
92. Murat, P.; Gormally, M.V.; Sanders, D.; Antonio, M.D.; Balasubramanian, S. Light-mediated in cell downregulation of G-quadruplex-containing genes using a photo-caged ligand. Chem. Commun. (Camb.) 2013, 49, 8453-8455.
93. Beaudoin, J.D.; Perreault, J.P. 5′-UTR G-quadruplex structures acting as translational repressors. Nucleic Acids Res. 2010, 38, 7022-7036.
94. Christiansen, J.; Kofod, M.; Nielsen, F.C. A guanosine quadruplex and two stable hairpins flank a major cleavage site in insulin-like growth factor II mRNA. Nucleic Acids Res. 1994, 22, 5709-5716.
95. Kumari, S.; Bugaut, A.; Huppert, J.L.; Balasubramanian, S. An RNA G-quadruplex in the 5′-UTR of the NRAS proto-oncogene modulates translation. Nat. Chem. Biol. 2007, 3, 218-221.
96. Arora, A.; Dutkiewicz, M.; Scaria, V.; Hariharan, M.; Maiti, S.; Kurreck, J. Inhibition of translation in living eukaryotic cells by an RNA G-quadruplex motif. RNA 2008, 14, 1290-1296.
97. Gomez, D.; Guédin, A.; Mergny, J.L.; Salles, B.; Riou, J.F.; Teulade-Fichou, M.P.; Calsou, P. A G-quadruplex structure within the 5′-UTR of TRF2 mRNA represses translation in human cells. Nucleic Acids Res. 2010, 38, 7187-7198.
98. Gomez, D.; Lemarteleur, T.; Lacroix, L.; Mailliet, P.; Mergny, J.-L.; Riou, J.-F. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by TERT RNA alternative splicing. Nucleic Acids Res. 2004, 32, 371-379.
99. Beaudoin, J.D.; Perreault, J.P. Exploring mRNA 3′-UTR G-quadruplexes: Evidence of roles in both alternative polyadenylation and mRNA shortening. Nucleic Acids Res. 2013, 41, 5898-5911.
100. Li, J.; Correia, J.J.; Wang, L.; Trent, J.O.; Chairesi, J.B. Not so crystal clear: The structure of the human telomere G-quadruplex in solution differs from that present in a crystal. Nucleic Acids Res. 2005, 33, 4649-4659.
101. Sissi, C.; Gatto, B.; Palumbo, M. The evolving world of protein-G-quadruplex recognition: A medicinal chemist's perspective. Biochimie 2010, 93, 1219-1230.
102. Darnell, J.C.; Jensen, K.B.; Jin, P.; Brown, V.; Warren, S.T.; Darnell, R.B. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001, 107, 489-499.
103. Wu, Y.; Brosh, R.M., Jr. G-quadruplex nucleic acids and human disease. FEBS J. 2010, 277, 3470-3488.
104. Paeschke, K.; Simonsson, T.; Postberg, J.; Rhodes, D.; Lipps, H.J. Telomere end-binding proteins control the formation of G-quadruplex DNA structures in vivo. Nat. Struct. Mol. Biol. 2005, 12, 847-854.
105. Lipps, H.J.; Rhodes, D. G-quadruplex structures: In vivo evidence and function. Trends Cell Biol. 2009, 19, 414-422.
106. Duquette, M.L.; Handa, P.; Vincent, J.A.; Taylor, A.F.; Maizels, N. Intracellular transcription of G-rich DNAs induces formation of G-loops, novel structures containing G4 DNA. Genes Dev. 2004, 18, 1618-1629.
107. Biffi, G.; Tannahill, D.; McCafferty, J.; Balasubramanian, S. Quantitative visualization of DNA G-quadruplex structures in human cells. Nat. Chem. 2013, 5, 182-186.
108. Lam, E.Y.; Beraldi, D.; Tannahill, D.; Balasubramanian, S. G-quadruplex structures are stable and detectable in human genomic DNA. Nat. Commun. 2013, 4, 1796, doi:10.1038/ncomms2792.